Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02576561
Other study ID # VAX 02-01
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received October 9, 2015
Last updated October 24, 2017
Start date November 2015
Est. completion date September 2018

Study information

Verified date October 2017
Source THEVAX Genetics Vaccine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to test the safety and effectiveness of the investigational study vaccine, called TVGV-1. The study will test the vaccine in women with high grade HPV cervical infection.


Description:

The purpose of the Phase 2a Study VAX 02-01 is to assess the safety and activity of TVGV-1 vaccine construct in achieving the absence of histologic HSIL (CIN2/3) (regression to LSIL or less) as assessed by biopsy at last study Visit 11, Day 270.

The objective of the TVGV-1 program is to develop a non-surgical alternative that is reliable, safe, and would avoid potential surgical risks such as preterm birth, perinatal mortality, risk of infertility, incontinence and disfigurement, as well as reduced cost and inconvenience for an otherwise economically productive young subject population.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date September 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

1. Female age 18 to 55 years

2. Written informed consent in accordance with institutional guidelines

3. Negative pregnancy test (urine and blood tests)

4. Women of child bearing potential must agree to use contraception through one menstrual cycle post end of study or if early withdrawal, through what would have been visit 11. Methods include intrauterine device or double barrier method, hormonal contraceptive in combination with a double barrier method.

5. Patients who have ONLY HPV 16 OR HPV 16 AND 18 and no other High-Risk HPV by Cobas test will be included.

6. Histologically confirmed, positive HSIL of CIN2+ or higher (only CIN2+/3 subjects will be selected) cervical biopsy, confirmed by external (independent) pathologist panel within the 12 weeks prior to enrollment. If the standard care biopsy is not available for evaluation by the independent pathologist, a fresh biopsy and endocervical curettage will be required. The extent of colposcopic HSIL disease should not involve more than two quadrants of the cervix. Biopsies should be taken from each affected quadrant

7. Adequate visualization of entire cervix, cervical lesion(s) and squamous-columnar junction

8. Normal electrocardiogram (ECG), laboratory values (chemistry, complete blood count) and urinalysis, as judged Grade 0-1 by per National Cancer Institute Common Toxicity Criteria (NCI-CTC)

9. Agrees to Loop Electrosurgical Excision Procedure (LEEP), Cold Knife Conization (CKC) or Hysterectomy being performed at the end of study according to the standard-of-care

Exclusion Criteria:

1. History of cancer (excluding basal cell carcinoma of the skin) including cervical cancer

2. Eastern Cooperative Oncology Group (ECOG) performance status >2 (See Appendix G)

3. Administration of any blood product within 3 months of enrollment

4. Active infection requiring antimicrobial treatment that would interfere with interpretation of adverse events, cutaneous reactions or efficacy. Treatment of minor concurrent infections should be limited to less than 10 days.

5. Administration of any vaccine within 8 weeks of enrollment and within 4 weeks for flu vaccine.

6. Participation in any study with an investigational compound or device within 30 days prior to signing informed consent

7. Any hematologic disorder involving platelets or clotting abnormalities or any condition requiring treatment with transfusions, anticoagulants except platelet inhibitors (NSAIDs as needed for pain are permitted)

8. Active drug or alcohol use or dependence that, in the opinion of the Site Investigator, would interfere with adherence to study protocol

9. Skin conditions that require consistent use of topical corticosteroids or other local or systemic therapy that may interfere with interpretation or description of skin-related adverse events linked to vaccination

10. The standard criteria for prospective clinical trials of medications developed by Drug-Induced Liver Injury Network (established by The National Institute of Diabetes and Digestive and Kidney Diseases) will be used to assess the laboratory test abnormalities. Normal range for these labs will typically be 5 - 40 IU/L for AST; 7 - 56 IU/L for ALT; 0.2 - 1.2 mg/dL for bilirubin. Subjects will be excluded if values are x 2-x 2.5 the upper limit

11. Evidence of hematopoietic, cardiovascular, hepatic, renal, neurologic, psychiatric, dermatologic, immune disorder, or other disease that may interfere with assessment of safety or efficacy of vaccine activity as indicated in study objectives

12. Any known allergic reaction to vaccine components

13. Any other medical condition(s) that, in the judgment of the Site Investigator, might interfere with the study or require treatment that might interfere with the study

14. Family member of the investigation study staff

15. Pregnant or breast-feeding

16. Inability to provide informed consent

17. A subject with a history or expectation of noncompliance with medications or treatment protocol

18. Receipt of (e.g. Gardasil® or Cervarix®) HPV preventative vaccines within 8 years of study enrollment

19. Excessive use of acetaminophen or other potentially hepatotoxic drugs

Study Design


Related Conditions & MeSH terms

  • High-Grade Squamous Intraepithelial Lesions
  • Human Papillomavirus
  • Squamous Intraepithelial Lesions of the Cervix

Intervention

Biological:
TVGV-1
Antigen + Adjuvant
GPI-0100
Adjuvant Alone
Placebo
Placebo

Locations

Country Name City State
United States Grady Memorial Hospital Atlanta Georgia
United States Complete Healthcare for Women Columbus Ohio
United States Red Rocks OBGYN Lakewood Colorado
United States Insearch-Tidewater Clinical Research Norfolk Virginia
United States Penn Fertility Care/Reproductive Research Unit Univ of Pennsylvania Philadelphia Pennsylvania
United States ProHEALTH Care Associates LLP Port Jefferson New York
United States Progressive Medical Research Port Orange Florida
United States Unified Women's Clinical Research Raleigh North Carolina
United States Visions Clinical Research - Tucson Tucson Arizona
United States Comprehensive Clinical Trials, LLC West Palm Beach Florida
United States Unified Women's Clinical Research Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
THEVAX Genetics Vaccine Clinical Research Management, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absence of histologic HSIL (CIN2/3) as assessed by biopsy at last study Visit 11, Day 270. The primary analysis for efficacy will be a comparison between subjects treated with and without the PEK fusion protein with respect to the percentage who present regression of HSIL at Day 270. Separate comparisons within each cohort will be performed using Fisher's exact test (or an appropriate analogue). No adjustment for multiple comparisons will be employed in these analyses. Additionally, a corresponding comparison across all study subjects combined will be performed, based on Cochran-Matel-Haenszel test stratified for cohort. DAY 270
Primary Assessment of cutaneous toxicities (i.e., size, induration and time to resolution of skin reactions to vaccine). Summaries of the data pertaining to the primary safety outcome of skin toxicity will be provided. Summaries will be provided for the within-cohort subsets of subjects treated with the active, and with the adjuvant alone; and the combined subsets across all three cohorts of subject treated with the active, with the adjuvant alone, and with the placebo. Serious adverse events will be described in narrative with the participant's demographics, treatment date, event, onset date, relationship to the study treatment and the descriptions of the actions and outcomes during this event. Any deaths occurring in the study will be summarized in narrative with the demographics, treatment duration, cause of death, date of death and additional information surrounding that serious adverse event. DAY 270
Secondary Absence of HPV16 in cervical cytological specimen. Absence of cervical dysplasia 6 months and 8 months after last dose of TVGV-1. The primary analysis for efficacy will be a comparison between subjects treated with and without the PEK fusion protein with respect to the percentage who present regression of HSIL at Day 270. Separate comparisons within each cohort will be performed using Fisher's exact test (or an appropriate analogue). No adjustment for multiple comparisons will be employed in these analyses. Additionally, a corresponding comparison across all study subjects combined will be performed, based on Cochran-Matel-Haenszel test stratified for cohort. DAY 270
Secondary Assessment of clinical or laboratory findings and other safety variables. Appropriate laboratory data will be transformed prior to analysis as defined in the Statistical Analysis Plan (SAP). Summaries will be presented for each evaluation time point, as well as for changes from baseline. Changes from baseline will also be presented using shift tables for selected laboratory parameters. DAy 270
See also
  Status Clinical Trial Phase
Completed NCT02740790 - Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females Phase 2
Completed NCT01845779 - Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal N/A
Completed NCT01159834 - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) N/A
Completed NCT01422356 - Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men N/A
Completed NCT02808832 - An HPV Vaccine Provider Intervention in Safety Net Clinics N/A
Completed NCT01456715 - Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later. Phase 3
Completed NCT02968420 - Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine Phase 4
Completed NCT02007421 - Study of the Prevention of Anal Cancer N/A
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Completed NCT02267876 - Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
Recruiting NCT01459289 - Psychosocial Effect of HPV Positivity N/A
Completed NCT01358097 - Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy N/A
Completed NCT01342978 - Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time N/A
Not yet recruiting NCT06434337 - Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
Terminated NCT02503111 - The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men N/A
Recruiting NCT02126189 - The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study N/A
Completed NCT01766284 - Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix N/A
Completed NCT01524003 - Chinese Cancer Prevention Study(CHICAPS) N/A
Recruiting NCT05026138 - Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Recruiting NCT03742869 - HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma